Healthcare Industry Questions AI Implementation Value at HIMSS26
Today's developments reveal a healthcare sector grappling with technological transformation while pharmaceutical innovation and industry consolidation continue at pace.
No single number captures it — the story is in the connections.
The HIMSS26 conference highlights the struggle to quantify AI's ROI, even as Blue Cross Blue Shield data suggests AI is already impacting medical billing practices. Meanwhile, significant pharmaceutical developments from Vertex and Xenon demonstrate continued progress in addressing unmet medical needs, while the Talkspace acquisition by UHS represents a major consolidation in behavioral health services. The FDA's reduced transparency in decision-making, particularly around a…
One pattern. Trace it.
- 01
A pattern worth naming
Watch for: 1) Insurance companies' responses to AI-driven billing practices, including potential policy changes within 60 days; 2) FDA advisory committee patterns, particularly for high-profile drug approvals; 3) Further consolidation in digital health space, especially involving traditional healthcare providers; 4) Implementation of AI ROI measurement frameworks emerging from HIMSS26 discussions within 90 days.
Ask your CFO whether the unit economics on every new service line still pencil under the new rate environment.
By Joseph Lancaster, Editor — with research from Pine Needle's intelligence layer.
The next argument lands tomorrow at 6 a.m. Pacific. Get it in your inbox →